Associations between high pre- or post-HCT ATG AUC and outcomes
| Outcome . | Pre-HCT AUC . | Post-HCT AUC . | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| MNCs . | Lymphocytes . | T cells . | CD4 T cells . | CD33 cells* . | MNCs . | Lymphocytes . | T cells . | CD4 T cells . | CD33 cells* . | |
| Relapse | ↓ | ↓ | ⇡ | ⇡ | ⇡ | |||||
| aGVHD (grade 2-4) | ⇣ | ↓↓ | ↓↓↓ | ↓↓ | ↓↓ | |||||
| cGVHD (moderate to severe; NST) | ↓ | ↓ | ↓ | |||||||
| OS | ⇡ | ⇣ | ||||||||
| RFS | ↑ | ⇣ | ||||||||
| cGRFS | ⇡ | ⇡ | ||||||||
| Outcome . | Pre-HCT AUC . | Post-HCT AUC . | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| MNCs . | Lymphocytes . | T cells . | CD4 T cells . | CD33 cells* . | MNCs . | Lymphocytes . | T cells . | CD4 T cells . | CD33 cells* . | |
| Relapse | ↓ | ↓ | ⇡ | ⇡ | ⇡ | |||||
| aGVHD (grade 2-4) | ⇣ | ↓↓ | ↓↓↓ | ↓↓ | ↓↓ | |||||
| cGVHD (moderate to severe; NST) | ↓ | ↓ | ↓ | |||||||
| OS | ⇡ | ⇣ | ||||||||
| RFS | ↑ | ⇣ | ||||||||
| cGRFS | ⇡ | ⇡ | ||||||||
Multivariate analysis was performed to determine the significance of the association between high (higher than median) pre- or post-HCT ATG AUC and each outcome. Only significant associations (P < .05) and trends toward significant associations (P = .05 to .15) are shown. ↑ or ↓ denotes that high AUC was associated with high or low risk of the outcome, with P value from .01 to <.05, ↑↑ or ↓↓ with P value from .001 to <.01, ↑↑↑ or ↓↓↓ with P value <.001, ⇡ or ⇣ with P value from .05 to .15.
NST, needing systemic therapy.
The association between AUC of ATG capable of binding to CD33 cells and relapse was determined in patients with acute myeloid leukemia/myelodysplastic syndrome/chronic myeloid leukemia/chronic myelomonocytic leukemia. For other outcomes, the association was determined in all patients (with any malignancy).